Silexion Therapeutics completes development plan for next-generation siRNA candidate SIL204; plans to present at 2025 ...
Silexion Therapeutics Corp, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the …